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ABSTRACT 
 
OBJECTIVE: To determine whether ERr 731 extract from the Rheum rhaponticum plant is 
effective in relieving symptoms of menopausal symptoms in women aged 45 to 55 years of age 
 
STUDY DESIGN: Review of all English language double blind randomized controlled trial 
studies from 2006 to 2009. 
 
DATA SOURCES: Randomized, controlled, double-blind, placebo controlled clinical trials 
comparing extract ERr731 to placebo were found in MEDLINE, OVID, and COCHRANE 
databases.  
 
OUTCOMES MEASURED: All three trials measured Menopause Rating Scale II.  Also 
determined in the review is the severity and number of hot flushes, and also a change in the 
quality of life.  Results for anxiety used the HAMA scale and results for changes in quality of 
life and well being were assessed on the Menopause specific Quality Of Life, Women’s Health 
Questionnaire, diary reports and the psychological general well being index. 
 
RESULTS:  All three trials showed results demonstrating significant results using extract 
ERr731 to decrease severity and number of hot flashes, increase the quality of life and also 
decrease overall menopause symptoms in women aged 45 to 55 years old.   Participants in Heger 
et al reported adverse events but no serious adverse events.  
 
CONCLUSIONS:  The results of the three trials show that extract ERr 731 is effective in 
reducing symptoms and severity of symptoms in menopause compared to placebo.  The extract 
however, has not been evaluated by many other studies or the FDA therefore true side effects 
and risks are not determined.  
 
KEY WORDS:  Menopause, climacteric, hot flushes.  
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INTRODUCTION 
 Menopause is the transition period that occurs in all women usually between the ages of 
45 and 55 when menstruation eventually stops. It is a natural biological termination of the ability 
to reproduce in the female population where eggs are no longer released from the ovaries. Some 
of the most common symptoms resulting include hot flushes and  mood swings which women 
search for treatments to find relief. Current treatments are available but aren’t always effective or 
they have significant side effects.  This paper evaluated randomized controlled double blind 
clinical trials comparing ERr731 extract to placebo in alleviating symptoms of menopause.  
 Relieving menopausal symptoms is common to encounter in all fields of PA practice. The 
majority of women experience some symptoms within their lifetime at an average age onset at 
51. About 85% of women have symptoms for 1 year, 25% for 5 years and about 15% of women 
have symptoms for 15 years or more (Manson , 2010).  In the transition from perimenopause to 
menopause, symptoms can disrupt the quality of life.  About one-third of women will consult a 
doctor annually because of menopausal symptoms but definite cost is unknown (Gunthrie 2003).     
After the age of 35, ovarian mass and fertility decline.  The process of depletion of primary 
follicles begins before birth and continues steadily until menopause. In perimenopause, intervals 
between menstrual cycles shorten by about 3 days due to an accelerated follicular phase. 
Follicle-stimulating hormone (FSH) levels rise, from altered folliculogenesis and reduced inhibin 
secretion. The consistently high FSH and low estradiol levels cause irregular hormone levels. 
During the transition into menopause, estradiol levels fall and estrone levels are preserved. FSH 
levels increase more than luteinizing hormone (LH) levels, due to the loss of inhibin, and 
estrogen feedback.  The change in hormones and age give rise to vasomotor symptoms (hot 
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flushes), menstrual cycle alterations, vaginal dryness and atrophy, sleep disturbances, mood 
changes, skin hair and nail changes, and osteoporosis.   
 Treatments for menopause symptoms include hormone replacement therapy.  The 
replacement of hormones can involve estrogen only, progestin only or a combination of both.   
There are oral combinations including Prempro and Premphase, patch combinations including 
Estraderm, Climara Pro or Combipatch.  Other forms of hormone replacement include vaginal 
suppositories, which are estrogen hormone only, including Estrace and Premarin.  Other alternate 
treatments include Selective Serotonin Reuptake Inhibitors (SSRI), soy, Black Cohosh, St. 
John’s Wart, 1200mg Calcium per day, and 400-800mg Vitamin D per day.  
 The method of treatment being proposed is that hormone replacement therapy is effective 
but has adverse side effects making them unsuitable for many patients. Some of the side effects 
include an increased risk of blood clot formation, cancer (especially breast cancer), 
cerebrovascular accidents and heart disease. The alternative treatments are not as affective and 
also cause adverse reactions and drug interactions including headache, dizziness, nausea, 
sedation, constipation, allergic reactions and drug interactions.  One of the major side effects is 
the interaction of St. John’s Wort and the possible adverse reaction with inducing metabolism of 
P450 drugs.  However, the extract ERr731 from the Rheum rhaponticum may provide 
satisfactory reduction in symptoms without any serious adverse effects.  
OBJECTIVE 
 The objective of this systematic review is to determine whether or not “Is extract ERr731 
from the Rheum rhaponticum effective in relieving menopausal symptoms in women aged 45 to 
55 years of age?” Although previous studies have shown some efficacy in hormone replacement 
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therapy and other alternative treatments, extract ERr731 from the Rheum rhaponticum plant has 
not previously been tested and thus efficacy of this extract is unknown.    
METHODS 
 Each of the three studies selected for this review meet the following criteria: The 
population included females aged 45-55 with climacteric complaints and a Menopause Rating 
Scale II score of > 18 who have an irregular menstrual cycle lasting for the past 12 months 
and/or their last menstruation was at least 3 months ago but no longer than 12 months ago. 
Exclusion criteria includes women who have regular menstrual cycles 3 months prior, PAP 
smear of class III/IV endometrial hyperplasia, concomitant medication that might impair the trial 
results, abnormal endometrium and breast, presence of concomitant disease, alcohol, smoking, 
caffeine, and a body mass index less than 18 kg/m
2
 or greater than 30 kg/m
2
.  The intervention 
used in the studies was 4mg tablets of ERr731 extract from the Rheum rhaponticum plant in 
tablet form. The treatment groups were compared to control groups given a visually matched 
placebo.  The main outcomes which were measured in a prospective, randomized, double-blind 
placebo controlled clinical study were anxiety, quality of life and hot flushes.   All English 
written articles were searched using key words like menopause, climacteric, and  hot flushes on 
OVID, Medline and Cochrane databases.  Each article was selected based on patient oriented 
evidence that matters (POEMS) and also were published in peer-reviewed journals between 1996 
and the present.  Table 1 includes the demographics of the 3 clinical trials which met the 
previously listed inclusion criteria.  Statistics reported include p values < 0.05 indicating clinical 
significance. 
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A.) Table 1 - Demographics & Characteristics of included studies 
Characteristics of studies included in systematic review of the effectiveness of ERr731 extract 
from the root of Rheum rhaponticum in the treatment of menopausal symptoms. 
Study Type # Age 
yrs 
Inclusion Criteria Exclusion 
Criteria 
W/
D 
Interventions 
Heger 
et al.  
Multicenter
prospective
double-
blind, 
placebo 
controlled, 
RCT 
110 45-
55 
Women with 
climacteric 
complains 
Menopause 
Rating Scale II     
( MRS II) of more 
than 22 points  
 
45 to 55 years old 
who have an 
irregular 
menstrual cycle 
lasting for the 
past 12 months 
and/or their last 
menstruation was 
at least 3 but no 
longer than 12 
months ago. 
Regular 
menstrual cycles 
3 months prior. 
PAP smear of 
class III/IV, 
endometrial 
hyperplasia, 
concomitant 
medications that 
might impair the 
trial results. 
64 1 enteric 
coated tablet 
of ERr731 
extract daily 
for 12 weeks 
Kaszkin
- Bettag 
2007 
Multicenter 
prospective
double-
blind, 
placebo 
controlled, 
RCT 
109 45-
55 
64 Enteric 
coated tablets 
of 250 mg of 
ERr731  
Kaszkin
- Bettag 
2009 
Multicenter
, 
prospective
, double-
blind, 
placebo 
controlled, 
RCT 
112 45-
55 
Women aged 45 
to 55 years old 
with irregular 
menstruation 
cycles during the 
past 12 months or 
last menstrual 
period > 3 but < 
12 months ago.  
Menopausal 
Rating Scale total 
score > 18 points 
indicating 
moderate to 
severe menstrual 
symptoms.  
Abnormal 
endometrium 
and breast, 
presence of 
concomitant 
diseases, use of 
predefined 
medications, 
pretreatment of 
menopausal 
symptoms 
alcohol, smoking 
and caffeine, and 
a body mass 
index less than 
18 kg/m
2
 or over 
than 30 kg/m
2
 
19 Enteric 
coated tablets 
containing 4 
mg of Rheum 
rhaponticum 
dry extract 
 
 
[*Ref = Reference number. See reference page for list of papers cited] 
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OUTCOMES MEASURED 
 Outcomes were measured using patient completed severity score surveys or 
questionnaires on anxiety, quality of life, or hot flushes.  In the article by Heger, et al. the 
outcomes were measured using a diary, MRSII, and  the menopause specific quality of life 
(MENQOL) score completed by the participants.   Kaszkin-Bettag et. al (2007)  use the 
Hamilton Anxiety Scale (HAMA),  Menopause Rating Scale II ( MRSII), the psychological 
general well being index, and Women’s Health Questionaire (WHQ) all completed by the 
participants to measure their outcomes.  In the article by Kaszkin-Bettag et al. (2009) the 
outcomes were measured using the MRS II and a diary completed by the participants also.  
RESULTS 
 The randomized controlled trials selected are double blind, prospective clinical trials 
analyzed with intention to treat and all participants in the trials who meet inclusion criteria 
received the same  ERr731 treatment or placebo, see table 1 for details.  Some data from each 
study is reported in dichotomus data yet other important data was unable to be converted into 
dichotomous.   
 In Heger Et al, a total of 55 participated for the placebo group and 54 participants were 
involved in the ERr731 treatment group.  Only7 participants from the control trial and 39 
participants from the ERr731 treatment group finished the experiment.   Discontinuation in the 
treatment group totaled 16.  One for lack of efficacy, 3 for violation of the smoking ban,   3 for 
adverse events, 2 for organizational reasons and 7 for other reasons not listed. In the placebo 
group, a total of 48 discontinued the study.  Thirty-one  discontinued for lack of efficacy, 1 for 
violation of the smoking ban, 1 for adverse events, and 16 for other reasons.  The  Heger et al 
study measured menopausal symptoms throughout the studying using the Menopausal Rating 
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Scale II, which includes 11 symptoms assessed on a 6-point rating scale from 0=not present to 5 
being most severe and a maximum score of 55 {17 Heger,M. 2006;}.  Table 2A shows results 
from the MRSII scores. On day 0 the treatment and placebo group had similar scores on the 
MRSII, 34.0+ 5.6 and 27.9+ 8.7 respectively.  By the end of the study, there were only 46 
participants in the ERr731 group but a significant decrease in the average MRSII score to 13.5 + 
6.3 showing a reduction in about 20 points.  The placebo group only had 12 participants who 
completed the study who reported an average  MRSII score of 27.9 + 8.7 {17 Heger,M. 2006;}. 
Table 2B shows results from the MENQOL, the Menopause-specific quality of life.  From the 
participants’ diaries the MENQOL score was calculated  on 4 domains: vasomotor, 
psychological, physical and sexual. The total score in each domain ranges from 1 to 8 and a 
lower score indicates a better quality of life.  In table 2B, the average MENQOL score for each 
group is listed on day 0 and day 84.  Both groups had similar scores when beginning the 
assessment, however, by day 84 the ERr731 score decreased more than the placebo group.   
Seventeen adverse events occurred in 16 women during the study; events included back pain, 
intercostals neuralgia, dizziness, viral infection of the upper respiratory tract, duodenal ulcer, 
cardiomyopathy, dysuria, weight gain, endometrium dysplasia and uterofibroma {17 Heger,M. 
2006;}.  Table 2D shows results for the adverse events and no events were considered to be 
related to the investigation medication {17 Heger,M. 2006;}.    
 
 
 
 
 
Table 2 A. Heger et al.: Severity scores on the MRSII 
Time  Group #
 
MRS II   95% CI SS
 
Day 
0 
ERr731 54 34.0 + 5.6 32.516-
35.558 
P < 
0.001 
Placebo 55 32.6 + 4.8 31.329-
33.944 
Day 
84 
ERr731 46 13.5 + 6.3 11.621-
15.379 
P < 
0.0001 
Placebo 12 27.9 + 8.7 22.381-
33.452 
 
Table 2 B.  Heger et al. reference #1: 
Reduction in  severity scores on the 
Menopause-specific Quality of Life 
Questionaire (MENQOL) 
Time  Group  Total SS 
Day 0 ERr731  4.72 P < 
0.05 Placebo 4.46 
Day 
84  
ERr731 2.69 P < 
0.05 Placebo 3.36 
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Table 2D. Heger et al. total adverse events. 
Group Participants with adverse events RR RRI ARI NNH 
ERr731 8/54= 0.1481 = 14.81% 1.02 = 
102% 
0.0186 = 
1.86% 
0.0027 = 
0.27% 
370.3 = 370 
Placebo 8/55 =  0.1454 = 14.54% 
In Kaszkin-Bettag et al, 2007,  the study focused on decreasing anxiety and the well 
being of women after the 84 day trial of ERr731 extract compared to the placebo. The Hamilton 
Anxiety Scale was used to determine a baseline and change in anxiety symptoms. The rating 
scale determines the severity of anxiety symptoms consisting of 14 items like muscle aches and 
pains, depressed mood, fears, insomnia, and tension.  Each of the categories are rated on a 0 (not 
present) to 5 ( severe) {16 Kaszkin-Bettag,M. 2007;}.   At baseline, day 0, the total HAMA score 
was similar between both placebo and treatment group. The ERr731 groups’ score was 27.5 + 
6.8 and the baseline score for the placebo group was 25.1 + 6.0.  On day 84, the group treated 
with ERr731 had an average score of  9.4 + 4.2.  The placebo group’s HAMA average total at the 
end of the trial decreased to 21.6 + 8.6. (See table 3a )  {16 Kaszkin-Bettag,M. 2007;}.  Another 
measurement to determine the success of ERr731 was the Psychological General Well-Being 
Index.  It is a self-administered quality of life assessment.  Table 3C shows the results and 
Table 2 C.  Heger et al. reference #1: Reduction in the number and severity of hot flushes during 
the past 24 hours recorded in participant diaries.  (p<0.0001).  
Time Group Total hot flushes /day Severity Number of specific  hot flushes 
Baseline 
Day 0 
  
ERr731 
 n=44 
16.2 + 7.7 Slight 7.6 + 2.5 
Moderate 5.5 + 3.6 
Severe 3.1 + 4.7 
Placebo 
n=46 
14.8 + 6.9 Slight 7.4 + 4.3 
Moderate 4.6 + 3.2 
Severe 3.1 + 6.9 
 Decrease 
in number 
on Day 28 
ERr731 
n=43 
-5.5 +  4.4 Slight -0.2 + 2.8 
Moderate -2.8 + 3.1 
Severe -2.6 + 4.6 
Placebo 
n=42 
0.0 + 3.2 Slight -0.6 + 2.8 
Moderate 0.2 + 2.5 
Severe 0.3 + 3.0 
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changes in the index reported by participants.  As referenced in the table, Day 0 scores were 
“low spirits mostly” or  “I have been up and down in spirits a lot”.  On day 84,  59.3% of 
participants reported being in good spirits mostly from the ERr731 treatment group compared to 
7.3% of  the placebo group {16 Kaszkin-Bettag,M. 2007;}.  Kaszkin-Bettag et all 2006 also used 
the MRSII to measure the changes in anxiety in particular for the study.  Table 3D represents 
differences in slight and severe anxiety at baseline and at the end of the trial.  The percent of 
severe anxiety in both treatment and placebo groups was more significant in number.  The 
participants that experienced severe anxiety was 48.1% in the treatment group and 45.5% in the 
placebo group. At the end of the study, the percent of women with severe anxiety in the 
treatment group was 1.9%, and in the placebo group it was 32.7% {16 Kaszkin-Bettag,M.2007;}. 
Table 3A.  Kaszkin-Bettag et al. 2007. 
Changes in the HAMA total score in 
women from the ERr731 and placebo 
groups.  (P<0.0001) 
Time Group  #  HAMA  total 
score 
Day 
0 
ERr731  54 27.5 + 6.8 
Placebo 55 25.1 + 6.0 
Day 
84 
ERr731 46 9.4 + 4.2 
Placebo 12 21.6 + 8.6 
Kaszkin-Bettag et al. 2009 measured a change in overall menopausal symptom change 
through the MRS scale and also looked at number of hot flushes women experienced in a 24-
hour time span. Table 4A shows the change in MRS score from day 0 to 84 in the ERr731  
Table 3B. Kaszkin-Bettag et al. 2007.  
Women’s Health Questionnaire (WHQ) 
result.  
 
Time Group WHQ score 
Day 0 ERr731 83.5+ 10.0 
Placebo 85.5 + 7.7 
Day 84 ERr731 105.9 + 16.6 
Placebo 77.0 + 25.5 
Table 3C. Kaszkin-Bettag et al 2007. Psychological General Well-Being Index results. 
Time Group Participants  Result RR RBI ABI NNT 
Day 
0 
ERr731 21/54 (38.9%) “Low spirits mostly” 1.78 0.784 = 
78.4% 
0.171 = 
17.1% 
5.85 = 
6 Placebo 12/55 (21.8%) 
ERr731 31/54 (57.4%) “ I have been up and 
down in spirits a lot” 
0.790 -0.267 =  
-26.7% 
-0.153 =        
-15.3% 
-6.54 = 
-7 Placebo 40/55 (72.7%) 
Day 
84 
ERr731 32/54 (59.3%) “In good spirits 
mostly” 
8.12 7.12 =  
712% 
0.52= 
52% 
1.92 = 
2 Placebo 4/55 (7.3%) 
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(decreased by 14.6  on  the MRS scale) and also demonstrated the change in  number of hot 
flushes women experienced per day {14 Kaszkin-Bettag,M. 2009;}.  
  Table 4A shows the change in MRS score from day 0 to 84 in the ERr731 (decreased by 
14.6 + 5.1) and the placebo group (decreased by (2.9 + 4.3).   Table 4B, displays the decrease in 
average number of hot flashes experienced by women throughout the intervention {14 Kaszkin-
Bettag,M. 2009;}.  Table 4C gives the evidence that a clinician needs to treat 28 women in order 
to harm one more in the treatment group. 
Table 4A Kaszkin-Bettag. Et al. 2009.  
MRS total score changes from  base 
line to day 84. 
Time Group MRS total 
score 
Day 0 ERr731 27.0 + 4.7 
Placebo 27.0 + 5.3 
Decrease in 
total score 
on Day 84 
ERr731 -14.6 + 5.1 
Placebo -2.9 + 4.3 
 
Table 4C. Adverse event reports.  
Group Number of patients with AEs RRI ARI NNH 
ERr 731 5/56 = 0.0892 = 8.92% 0.664 = 
66.4% 
0.0356 = 
3.56% 
28.0 
Placebo 3/56 = 0.0536 – 5.36% 
DISCUSSION 
 The randomized controlled trials in this review of extract ERr 731 in the treatment of 
menopausal symptoms showed that the medication can safely treat the symptoms and improve 
Table 3D  Kaszkin-Bettag et al 2007 .  Anxiety symptoms of the menopause rating scale II. 
Time Group Severity  # %  RR RBI ABI NNT 
Day 
0 
ERr731 Slight 3/54 5.6 7.727 6.745 0.371 2.695 
Placebo Slight 3/55 5.5 
ERr731 Severe 26/54 48.1 1.057 0.057 0.026 38.46 
Placebo Severe 25/55 45.5 
Day 
84 
ERr731 Slight 12/54 22.2 1.11 0.11 0.022 45.45 
Placebo Slight 11/55 20.0 
ERr731 Severe 1/54 1.9 0.058 -0.942 -0.308 3.25 
Placebo Severe 18/55 32.7 
Table 4B.  Kaszkin-Bettag et al. 2009. 
Number of hot flashes reported in 
diaries by participants. 
Time Group Number of hot 
flushes 
Day 0 ERr731 11.4 + 5.8 
Placebo 12.1 + 6.0 
Day 84 ERr731 2.8 + 2.8 
Placebo 11.4 + 6.8 
Merlino, ERr731 and Menopausal Women    12 
 
quality of life.   The reduction of menopausal symptoms, especially anxiety and hot flushes, and 
an increase in quality of life was consistently demonstrated within all 3 clinical trials.  Since 
there is numerous data collected, a reference for the abbreviation meanings is helpful to obtain 
more information from the charts.  Risk ratio (RR) is the ratio of the probability of developing an 
outcome in a specified time among those who received the treatment compared with the 
probability of developing the outcome among those who didn’t receive the treatment. Relative 
risk increase (RRI) and absolute risk increase (ARI) are used to determine the increase risk of a 
bad thing happening. Alternatively, relative benefit increase (RBI) and absolute benefit increase 
(ABI) determine the probability of a good thing happening. Finally, the number needed to harm 
(NNH) or number needed to treat determines how many people need to be treated in order to 
have 1 increase in a bad event or 1 increase in a good event respectively.   Heger et al. and 
Kaszkin-Bettag 2009  reported adverse events.  The calculations determined from Table 2D 
demonstrate that for every 370 women who had the experimental treatment, there was 1 more 
incidence of adverse reaction in the group that had a placebo, even though the adverse events 
were not necessarily related to the treatment {17 Heger,M. 2006;}.  .  In Kaszkin-Bettag et al 
2006, showed similar results for successful treatment. In reference to table 3c the number needed 
to treat decreased from 6 to 2 by the end of the trial. Therefore, a clinician would need to treat 
only 2 mothers to relieve menopausal symptoms, therefore increasing the quality of life.   The 
most impressive result from table 3D shows changes in anxiety, specifically by the end of the 
trial, a clinician would need to treat 3.25 women in order to have one more decrease in severe 
anxiety compared to baseline where 38.46 women needed treatment before there was one 
reduction in severe anxiety.  Even though the extract seems effective, it had not been evaluated 
by the food and drug administration, it is only available online through one distributer.  The 
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limitations in the clinical trials include the discontinuation in treatment within both groups in all 
three studies.  In Heger et al,  and Kaszkin-Bettag et all 2006, 39 women in the treatment group 
and only 7 women in the control group completed the study.  However, all participants, 54 from 
treatment and 55 from control group were followed up in a 48 observational study. In Kaszkin-
Bettag et all 2009,  47 women in the treatment group and 46 women in the control group 
completed the study as planned.  With the participants who were lost, all were entered into a 52 
week observational study for follow up.  
CONCLUSION 
 The studies reviewed demonstrate that extract ERr 731 is effective in reducing 
menopausal symptoms and increasing the quality of life for women suffering from symptoms.  
However, there are not many trials with varying amounts of extract.  In all 3 clinical trials 
reviewed, 4mg tablets were used.   Future studies should focus varying treatment dosages and 
treatment start time to determine if symptoms could be prevented or present with minimal 
severity.  Table 1 shows the inclusion and exclusion criteria which is significant and challenging 
for an entire population to follow.  Future studies should have trials on women who do smoke, 
drink, have dysplasia and other exclusion criteria that were listed to make sure that more women 
could take the treatment and be successful rather than a small subset of women.  Finally, the 
studies reviewed for this paper were all completed in Germany, for completeness, a study should 
be conducted in the United States to determine if the extract could reduce physical and mental 
parameters of menopausal symptoms within a different culture.   
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